Microbot Medical Inc. (NASDAQ:MBOT - Get Free Report) shares crossed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $1.36 and traded as high as $2.11. Microbot Medical shares last traded at $1.65, with a volume of 33,273,909 shares.
Wall Street Analyst Weigh In
Separately, HC Wainwright reissued a "buy" rating and issued a $9.00 price objective on shares of Microbot Medical in a report on Thursday, April 10th.
View Our Latest Report on MBOT
Microbot Medical Stock Performance
The business's 50 day moving average price is $1.68 and its 200-day moving average price is $1.39. The firm has a market capitalization of $83.91 million, a PE ratio of -2.99 and a beta of 1.40.
Microbot Medical (NASDAQ:MBOT - Get Free Report) last released its quarterly earnings results on Wednesday, March 26th. The biotechnology company reported ($0.20) EPS for the quarter, missing analysts' consensus estimates of ($0.18) by ($0.02). As a group, analysts anticipate that Microbot Medical Inc. will post -0.71 earnings per share for the current year.
Institutional Investors Weigh In On Microbot Medical
An institutional investor recently bought a new position in Microbot Medical stock. Renaissance Technologies LLC acquired a new position in shares of Microbot Medical Inc. (NASDAQ:MBOT - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 105,658 shares of the biotechnology company's stock, valued at approximately $118,000. Renaissance Technologies LLC owned about 0.52% of Microbot Medical as of its most recent filing with the SEC. Institutional investors own 16.30% of the company's stock.
Microbot Medical Company Profile
(
Get Free Report)
Microbot Medical Inc, a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces.
See Also
Before you consider Microbot Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Microbot Medical wasn't on the list.
While Microbot Medical currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering when you'll finally be able to invest in SpaceX, Starlink, or X.AI? Enter your email address to learn when Elon Musk will let these companies finally IPO.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
